Key Highlights

  • Median progression-free survival was 15.0 months in 43 frontline lung cancer patients on silevertinib, with a 60% objective response rate unchanged and median follow-up of 15.9 months, as of an October 7, 2026 data cutoff.
  • Third-quarter net loss widened to USD 10.0 million from USD 8.5 million, as general and administrative expense rose to USD 5.1 million from USD 3.5 million on intellectual property and tax costs.
  • Cash, cash equivalents and investments were USD 102.0 million at September 30, 2026, which the company believes funds operations into the second half of 2028.
  • The company plans a global Phase 3 trial of about 300 patients, with a potential start in the second quarter of 2027, and said it must raise substantial additional Capital to run it.

Updated Phase 2 Data Lands With the Quarterly Filing

Black Diamond Therapeutics (NASDAQ:BDTX) filed its Quarterly Report on November 10, 2026 and announced updated frontline results the same day. Silevertinib is a brain-penetrant EGFR inhibitor for non-small cell lung cancer. Of 43 patients with non-classical mutations, 18 (42%) remained on therapy, disease control was 93%, and median duration of response was 13.8 months. Patients without brain metastases had median progression-free survival of 23.5 months, while those with untreated brain metastases had 12.2 months. The CNS response rate in seven patients with measurable brain lesions was 86%, the company said. No new safety signals were observed, and common side effects included rash, stomatitis, diarrhea and paronychia.

FDA Feedback Shapes the Phase 3 Plan

After an October 1, 2026 meeting, the FDA gave feedback on population, design, endpoints and dose. The company chose 150 mg once daily for pivotal work, and Phase 3 would compare it with afatinib or osimertinib in about 300 patients with brain metastases. CNS response is the primary endpoint for a potential Accelerated Approval filing, and progression-free survival for full approval. Safety data from an ongoing 20-patient cohort must be submitted first. The company expects CNS data in 2029 if the trial starts in the second quarter of 2027. Most patients needed dose changes, and 19% discontinued because of adverse events.

Spending, Runway and the Funding Gap

Research and development was USD 7.0 million in the quarter against USD 7.4 million, with USD 2.5 million of new glioblastoma trial costs offsetting lower lung cancer spending. The nine-month net loss was USD 29.0 million, compared with Net Income of USD 37.5 million a year earlier, when a USD 70.0 million upfront license payment was recorded; no Revenue was booked in 2026. Operating cash use was USD 26.5 million over nine months. The runway estimate rests on assumptions that may prove wrong, and the Phase 3 and any launch would need substantial new capital, which could dilute holders. Accumulated Deficit was USD 493.7 million.

Where Things Stand

It depends on the next steps. Black Diamond Therapeutics (NASDAQ:BDTX) has durable early responses, a 60% response rate and an FDA-reviewed path, but the data come from a single-arm trial of 43 patients and most patients needed dose adjustments. Financially, the loss widened to USD 10.0 million in the quarter, and USD 102.0 million of cash covers only part of a global Phase 3. Watch Cohort 4 safety data at 150 mg, the planned second-quarter 2027 trial start, the glioblastoma trial and any financing.